Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects With Schizophrenia

NCT00604279 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.

NCT NCT00604279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00604279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects With Schizophrenia
Lead sponsor
Xian-Janssen Pharmaceutical Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
January 31, 2009
Enrollment
452 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia